Sales Incentive Plan for Pharma Reps: How to Set Targets and Design a Plan That Works

FreeScore your brand plan before management does. Send me the scorecard

In more than twenty years of marketing medicines and consumer health products in Egypt, Saudi Arabia and the Gulf, I have sat in many meetings where a new incentive plan was announced, and in many more where the field quietly worked out how to beat it. The lesson I keep relearning is simple: reps do what the plan pays for, not what the slide says the company wants. If the two are different, the plan wins.

This guide is for first-line and regional managers of medical and pharmacy rep teams, Rx and OTC, in Saudi Arabia and the GCC, and for reps who want to understand how their plan works or who hope to manage a team one day. If you are new to managing, the guide for the first-line pharma sales manager covers the wider role; this one focuses on targets and incentives.

What Is a Sales Incentive Plan?

Most field teams are paid a fixed monthly salary plus a variable incentive. The incentive part is governed by the SIP. Some companies call it a bonus scheme, an incentive compensation plan or simply “the IC plan”; the idea is the same. A complete plan answers six questions:

1. Who is eligible, and from when?
2. How much variable pay is on offer at 100% of target?
3. Which measures decide the payout, and what weight does each carry?
4. What target applies to each rep for each measure?
5. How does payout change above and below target?
6. When is it paid, and what happens with leavers, joiners, vacancies and territory changes?

The plan has two jobs. The first is to direct effort: it tells reps which products, customers and behaviours matter most this year. The second is to reward fairly: people who deliver more, in ways the company values, should earn more. A plan that does one job and not the other fails. A fair plan that points at the wrong things buys the wrong results; a well-aimed plan that feels unfair loses its best people.

Andris Zoltners, Prabhakant Sinha and Sally Lorimer, in The Complete Guide to Sales Force Incentive Compensation (2006), make the point that incentive pay is only one of the levers that drive sales force performance, alongside hiring, training, coaching, territory design and the information reps work with. An incentive plan cannot fix a team that is badly sized, badly trained or badly led. Keep that in mind before you redesign the plan to solve a problem that lives somewhere else.

How Do You Decide the Pay Mix Between Fixed and Variable?

Pay mix is the split of target total pay between salary and incentive at 100% of target. It is written as two numbers that add to 100, such as 80/20, meaning 80% fixed and 20% variable at target. Zoltners, Sinha and Lorimer describe pay mix as a design choice that should follow how much the salesperson influences the buying decision compared with other factors such as the brand, marketing, pricing and access. In pharma, the answer differs sharply by role:

• Rx reps calling on doctors. The rep is one influence among many: clinical evidence, guidelines, formulary decisions, hospital tenders and the patient’s ability to pay. Results take months to show, and territory data may be patchy.
• Key account managers in hospitals. Large, slow decisions made by committees, where the account manager matters a great deal but timing is uneven.
• OTC and consumer health reps in pharmacies. The rep has a more direct effect on orders, stock, shelf position and counter recommendation, and sell-in is measured order by order.

The table below shows how three fictional companies might set pay mix differently. These are illustrations of the logic only, not industry norms; your company’s market data, budget and HR policy decide the real numbers.

Two warnings. First, a high variable share in a role where results are hard to measure makes pay feel like a lottery, and good reps leave after a run of bad luck. Second, a very low variable share sends the message that results do not matter, and the plan stops directing effort at all. Pick the mix deliberately, write down why, and keep it stable for long enough that people trust it.

What Are the Components of a Sales Incentive Plan?

A few practical notes on each:

• Keep measures to two or three. Each added measure dilutes the others. When a plan has many measures, each worth a small share, reps cannot keep them in mind and focus on whichever is easiest.
• Weights should add to 100% of the target incentive, and no measure should be so small that it does not change behaviour.
• Threshold is a balance. Too high, and a rep who falls behind early gives up on the period. Too low, and the plan pays for results that would have happened anyway.
• Caps are a judgement call. A cap protects the budget from data errors, sudden tender wins or a competitor’s stock-out that has nothing to do with the rep. But a cap set too low tells your best people to stop selling once they reach it, or to push orders into the next period.
• Payout frequency in OTC interacts with stock loading. A monthly plan paid on sell-in invites reps to push stock into pharmacies at month-end. A quarterly plan, or a plan that includes a sell-out or stock-health check, reduces that.

How Do You Set Sales Targets Fairly?

Most of the arguments I have seen about incentive plans were really arguments about targets. Goal-setting theory explains why targets matter so much. Edwin Locke and Gary Latham, in A Theory of Goal Setting and Task Performance (1990), summarised a large body of research showing that specific, difficult goals lead to higher performance than vague goals such as “do your best”, provided people are committed to the goal, have the ability to reach it and receive feedback on progress. The condition matters as much as the finding: a goal people see as impossible loses their commitment, and then it stops working.

Top-down, bottom-up, or both?

• Top-down: the national forecast is split by region and territory using a formula. It is consistent and adds up to the budget, but can ignore what is happening on the ground.
• Bottom-up: each rep and manager builds a forecast account by account. It uses local knowledge but tends to come in low, because nobody volunteers a hard target.
• Both: set the top-down split first, then ask first-line managers to challenge it territory by territory with evidence, and adjust within the total. This is the approach I recommend.

What should go into the split?

• Market potential. How much of the relevant patient population, prescriber base or pharmacy turnover sits in the territory. Use the best data you have: market data where you can access it, the number and type of target prescribers, the number and size of pharmacies, population figures.
• History. What the territory sold last year. Useful, but dangerous alone: splitting only on history punishes the rep who grew the territory last year and rewards the one who did not.
• Territory size and travel. A rep covering a wide area with long drives between cities cannot see as many customers as a rep in one dense city district.
• Product life stage. A launch product has little history, so its targets should lean on potential and on activity milestones early on. A mature product has a stable base, so growth targets should be modest and realistic.
• Known events. A vacancy for part of the year, a key account closing, a new hospital opening, a competitor launch, or a supply shortage you already know about.

A simple and defensible method is a weighted index: for example, 60% weight on the territory’s share of market potential and 40% on its share of last year’s sales. Those weights are an illustration; choose yours by testing which split best matches the territories you know are strong and weak. Run the numbers, then sit with each first-line manager and look at the outliers together.

The risk at both ends

The last point in the right-hand column is the one compliance teams worry about, and they are right to. A target that cannot be reached honestly is an invitation to cut corners. When I see one territory with a target far above its potential, I treat it as a risk to fix, not a stretch to admire.

FreeScore your brand plan before management does. Send me the scorecard

Which Measures Work for Rx Teams and Which for OTC Teams?

Steven Kerr’s article “On the Folly of Rewarding A, While Hoping for B” (1975, Academy of Management Journal) is the best short warning I know for anyone choosing measures. Kerr showed how organisations routinely reward one behaviour while hoping for another, then act surprised when they get what they rewarded. In a field team, that means: if you pay for calls and hope for prescriptions, you will get calls.

Rx teams

For prescription medicines, the question is whether you can see sales or prescribing at the level of one rep’s territory. In some GCC markets you can see it only at region, distributor or key account level, and part of public hospital volume moves through tenders the rep does not control. When territory-level data is weak:

• Pay the sales component at the lowest level where the data is trustworthy, such as the region or a defined group of key accounts, and say so openly.
• Add quality measures a manager can verify: coverage of the agreed priority customer list, completion of product training and certification, and the quality of calls observed on joint visits against an agreed standard.
• For hospital and key account roles, consider account plans with agreed milestones, but make sure each milestone is legitimate (for example, a formulary submission completed with medical affairs) and does not reward the decision itself.

OTC and consumer health teams

Pharmacy teams usually have more to work with: orders by account, distributor sell-in by area, and sometimes sell-out data from pharmacy chains or retail audits. Useful measures include:

• Sales value against target, by territory or by account group.
• A focus-product or new-listing measure for launches and priority lines.
• Distribution or listing in target pharmacies, checked by audit.
• Shelf and display execution against an agreed standard, verified by photos or manager visits. The guide to pharmacy counter selling covers what good execution looks like at the counter.

Where sell-out data exists, a plan that pays partly on sell-out or checks stock levels protects against month-end loading. Where only sell-in exists, quarterly payout and a check on returns or stock weeks do part of the same job.

Should You Pay for Activity or for Results?

Activity measures count what a rep does: calls, visits, coverage, frequency. Result measures count what happens because of it: sales, new listings, growth. Activity is easier to measure and fully within the rep’s control; results are what the company needs but are affected by many things outside the rep’s control.

When the incentive rests on call counts, the incentive is for calls, not good calls. Reps learn which customers are quick to see, which pharmacies will sign a call report in thirty seconds, and how to log visits that add nothing. Kerr would recognise the pattern at once. Managers then spend their time auditing call reports instead of coaching.

There is also a motivation cost. Edward Deci and Richard Ryan’s self-determination theory (1985) distinguishes intrinsic motivation, doing the work because it is interesting or meaningful, from extrinsic motivation driven by outside rewards. Their research suggests that rewards experienced as controlling can weaken intrinsic motivation, while people do better when they feel a sense of autonomy, competence and relatedness. A plan that pays a rep to tick boxes treats them as someone to be controlled. A plan that pays for results and leaves the rep room to decide how to get there respects their judgement, and the best reps notice the difference.

Activity measures still have a place:

• New reps in their first months, who cannot yet influence results. A 30-60-90 day plan with milestones can carry part of their incentive until they have a full year in the territory.
• Launches, where early coverage of target customers is the right thing to reward before sales data arrives.
• Coverage of the agreed priority list rather than raw call numbers. The rep call plan calculator helps size a realistic call plan before you attach any measure to it.

Most importantly, use activity data for coaching rather than pay. A manager who sees a rep covering the wrong customers has a field coaching conversation to have, not a payout to cut.

Should the Plan Reward the Team or the Individual?

An individual component makes each rep responsible for their own territory and makes high performers visible. A team component encourages reps to share what works, cover for each other during leave and vacancies, and stop arguing about who should get credit for a hospital order that several reps influenced.

The risks run in opposite directions. Pure individual plans can create competition between reps who share a key account, and arguments about territory boundaries. Pure team plans can let weaker performers ride on the strong. A common answer is a blend, for example a large individual component and a smaller team or regional component. The exact split is a design choice; base it on how interdependent the team really is and on where your data is trustworthy.

For first-line managers themselves, a plan that pays mostly on the whole team’s result, with a component for team development such as coaching completed and reps retained, sends the right message about what the job is.

How Do You Keep an Incentive Plan Compliant?

In Saudi Arabia the Saudi Food and Drug Authority (SFDA) sets the code governing the promotion of medicines, and other GCC regulators have their own codes. Company policies, especially at multinational companies, are often stricter. The incentive plan has to live inside both. In practice that means:

• No reward for off-label sales or promotion. If a product is used outside its approved indication, those sales should not be targeted or encouraged, and the plan should not reward a rep for them. Talk to your medical and compliance teams about how to handle this in your data.
• No measure that rewards a prescribing decision directly in a way the code or policy forbids, and nothing that links a healthcare professional’s decisions to anything of value they receive.
• Quality measures must be compliant too. If you score call quality, the scorecard should include staying within approved claims and using approved materials. The pharma selling skills guide describes what a compliant call looks like.
• Consider a compliance gate. Some plans state that a confirmed breach of the promotion code or company policy affects incentive eligibility for the period. If you use one, write it clearly, apply it consistently and agree it with HR and legal.
• Watch targets as well as measures. As covered above, impossible targets create pressure that can push people toward claims they should not make.

I deliberately do not quote specific limits or article numbers here, because codes are updated. Check the current SFDA code and your company’s procedures. The SFDA marketing compliance checklist gathers the points marketing and field teams need in one place.

How Does the Payout Work in Practice? A Worked Example

Here is a fictional plan for an OTC pharmacy rep, Rep 1, at a fictional Company C. Every number is invented to show the mechanics; none is a recommendation or an industry norm.

• Target incentive: SAR 24,000 a year at 100% of target, paid quarterly, so SAR 6,000 a quarter.
• Measure 1, sales value against target: weight 70%, so SAR 4,200 a quarter at target.
• Measure 2, quality scorecard (coverage of the agreed priority pharmacy list, shelf execution audits and a joint-visit call standard that includes compliance): weight 30%, so SAR 1,800 a quarter at target. Paid on the score achieved, capped at 100%.
• Threshold on sales: 80% attainment. Below 80%, the sales component pays nothing. At 80% it pays 50% of the component.
• Between threshold and target: payout rises from 50% to 100% of the component, 2.5 points of payout for each point of attainment.
• Accelerator above target: 4 points of payout for each point of attainment above 100%.
• Cap: the sales component stops rising at 120% attainment, which pays 180% of the component.

Assume Rep 1 scores 100% on the quality scorecard in each case, so only sales attainment changes:

Four things are worth noticing. The step at the threshold is large: one point of attainment, from 79% to 80%, is worth SAR 2,100 in this plan, which is exactly the kind of cliff that tempts people to pull orders forward. A smaller payout at threshold softens that. The accelerator makes over-delivery attractive: the last 20 points of attainment are worth more than the 20 points before target. The cap means a rep at 130% earns the same as one at 120%, so a rep who is near the cap late in the quarter has a reason to hold orders back; that is the trade-off you accept for cost control. And the quality component keeps paying even in a bad sales quarter, which protects the behaviours you want when results dip for reasons outside the rep’s control.

You do not need a spreadsheet to test variations of this. The free sales incentive calculator runs exactly this kind of payout maths: enter the target incentive, weights, threshold, accelerator and cap, and see what each level of attainment pays. Try moving the threshold or the cap and watch what happens to the totals before you commit to a design.

How Do You Communicate the Plan to the Team?

Locke and Latham’s research is clear that goals work through commitment and feedback. A rep who does not understand the plan cannot commit to it, and a rep who cannot see their progress gets no feedback from it. A good plan document has:

• A one-page summary with the measures, weights, threshold, target, accelerator, cap and payout dates.
• The rep’s own targets for each measure and period.
• Worked examples at three or four attainment levels, like the table above.
• The rules for special cases: joiners and leavers, long leave, territory changes, vacancies, product shortages and data corrections.
• A clear route for questions and disputes, with a named person and a time frame for answers.

Then give reps regular feedback: a monthly or weekly attainment report, discussed in one-to-ones. The best incentive plan I ever saw in action was not the cleverest. It was the one every rep could explain in two minutes, with a report that told them each week where they stood. Sharing the plan is also a coaching moment: new reps on a pharmaceutical sales rep training program should learn how they are paid in their first weeks, not discover it at their first payout.

How Should You Review the Plan Each Year?

A practical annual review covers these questions:

Resist the urge to redesign the plan every year. Reps need time to learn a plan and trust it. Targets must change annually; measures and weights should change when strategy changes, for example a major launch or a shift from Rx to OTC focus; the basic structure should stay steady for several years if it works.

What Are the Most Common Sales Incentive Plan Mistakes?

• Too many measures. Six measures at small weights each, and reps chase the easiest one.
• Paying for call counts. You get more calls, not better ones.
• Targets set on history alone. Last year’s best performer gets the hardest target and the weakest gets the easiest.
• Measuring individuals with team-level data. Reps see the unfairness quickly and stop trusting the plan.
• A cliff at the threshold. A big jump in payout at one attainment point invites pulling orders forward or holding them back.
• A cap set too low. Top performers stop selling, or push orders into the next period, once they hit it.
• Monthly sell-in plans in OTC with no stock check. Month-end loading, then returns and discounting.
• Ignoring compliance. Any measure that rewards off-label sales or pressure beyond approved claims is a risk to the company and the rep.
• A plan nobody can explain. If a rep cannot calculate their own payout, the plan will not direct their effort.
• Changing the plan mid-year. Unless something has gone badly wrong, mid-year changes destroy trust in every future plan.

Key Takeaways

• A sales incentive plan is the rulebook that turns results into variable pay; reps do what it pays for
• Choose pay mix by how much the rep influences the sale and how fairly results can be measured
• Keep to two or three measures, with weights that add to 100% and each big enough to matter
• Threshold, target, cap and accelerators each change behaviour; test them with worked examples
• Set targets top-down from market potential and history, then check them bottom-up with managers
• Specific, difficult but attainable goals work; impossible ones lose commitment (Locke and Latham, 1990)
• Rx teams may need regional or team measures; OTC teams can usually measure by account
• Pay mostly for results and verifiable quality; use activity data for coaching
• Stay inside the SFDA code and company policy; never reward off-label sales
• Explain the plan on one page, report progress often, and review it once a year

Frequently Asked Questions

What to Do Next

Take your current plan and write it out on one page using the components table above. If you cannot fill a row, that is the first gap to close. Then check your targets against market potential for your three strongest and three weakest territories, and run your plan through the sales incentive calculator at 80%, 100% and 120% attainment to see whether the payouts tell the story you want.

Before the plan goes to the team, take it to compliance and HR, and prepare worked examples for your one-to-ones. When reps raise concerns about targets, treat them like customer objections: listen first and look for the real issue, as the guide to sales objection handling describes. And if you are building the team as well as the plan, start with the role itself: the guide to what a medical representative does sets out the job your plan is meant to reward.